Literature DB >> 17722905

Synthesis and biological activities of new checkpoint kinase 1 inhibitors structurally related to granulatimide.

Elisabeth Conchon1, Fabrice Anizon, Bettina Aboab, Michelle Prudhomme.   

Abstract

In the course of structure-activity relationship studies on granulatimide analogues, new pyrrolo[3,4-c]carbazoles in which the imidazole heterocycle has been replaced by a five- or a six-membered ring bearing one or two carbonyl functions have been synthesized. Their checkpoint kinase 1 (Chk1) inhibitory properties and their in vitro antiproliferative activities toward three tumor cell lines-murine leukemia L1210 and human colon carcinoma HT29 and HCT116 have been determined. The results of molecular modeling in the ATP binding pocket of Chk1 are described. Among the newly synthesized compounds, compounds 13 and 16, in which the imidazole was replaced by a quinone and a hydroquinone and which bear a hydroxy group on the indole moiety, are the most potent Chk1 inhibitors in this series with IC50 values of 27 and 23 nM, respectively.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17722905     DOI: 10.1021/jm070664k

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Facile synthesis of indole- or benzofuran-fused benzo[a]carbazole-1,4-diones using a tandem two-step reaction sequence.

Authors:  Shanghui Tu; Chunyong Ding; Wenxiang Hu; Fulong Li; Qizheng Yao; Ao Zhang
Journal:  Mol Divers       Date:  2010-03-14       Impact factor: 2.943

2.  A Chemo- and Regioselective Tandem [3 + 2]Heteroannulation Strategy for Carbazole Synthesis: Combining Two Mechanistically Distinct Bond-Forming Processes.

Authors:  Emma Campbell; Andrea Taladriz-Sender; Olivia I Paisley; Alan R Kennedy; Jacob T Bush; Glenn A Burley
Journal:  J Org Chem       Date:  2022-03-18       Impact factor: 4.354

Review 3.  Marine pyrrolocarbazoles and analogues: synthesis and kinase inhibition.

Authors:  Sébastien Deslandes; Stefan Chassaing; Evelyne Delfourne
Journal:  Mar Drugs       Date:  2009-12-01       Impact factor: 5.118

Review 4.  G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer.

Authors:  N Bucher; C D Britten
Journal:  Br J Cancer       Date:  2008-01-29       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.